PLK

Sigaling Pathway Map

Research Area

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S1109 BI 2536 <1 mg/mL 21 mg/mL 100 mg/mL
S2235 Volasertib (BI 6727) <1 mg/mL 20 mg/mL <1 mg/mL
S1362 Rigosertib (ON-01910) 95 mg/mL 95 mg/mL <1 mg/mL
S2193 GSK461364 <1 mg/mL 10 mg/mL 30 mg/mL
S1485 HMN-214 <1 mg/mL 12 mg/mL <1 mg/mL
S7552 CFI-400945 <1 mg/mL 100 mg/mL 100 mg/mL
S2898 MLN0905 <1 mg/mL 97 mg/mL <1 mg/mL
S7248 Ro3280 <1 mg/mL 100 mg/mL 100 mg/mL
S7255 NMS-P937 (NMS1286937) <1 mg/mL 42 mg/mL 10 mg/mL
S7720 SBE 13 HCl <1 mg/mL 95 mg/mL <1 mg/mL

Isoform-specific Inhibitors

Catalog No. Information Product Use Citations Product Validations
S1109

BI 2536

BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.

S2235

Volasertib (BI 6727)

Volasertib (BI 6727) is a highly potent Plk1 inhibitor with IC50 of 0.87 nM in a cell-free assay. It shows 6- and 65-fold greater selectivity against Plk2 and Plk3. Phase 3.

S1362

Rigosertib (ON-01910)

Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Phase 3.

S2193

GSK461364

GSK461364 inhibits purified Plk1 with Ki of 2.2 nM in a cell-free assay. It is more than 1000-fold selective against Plk2/3. Phase 1.

S1485

HMN-214

HMN-214 is a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.

S7552New

CFI-400945

CFI-400945 is an orally active, potent and selective polo-like kinase 4(PLK4) inhibitor with Ki value of 0.26 nM.

S2898

MLN0905

MLN0905 is a potent inhibitor of PLK1 with IC50 of 2 nM.

S7248

Ro3280

RO3280 is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.

S7255

NMS-P937 (NMS1286937)

NMS-P937 (NMS1286937) is an orally available, selective Polo-like Kinase 1 (PLK1) inhibitor with IC50 of 2 nM, 5000-fold selectivity over PLK2/PLK3. Phase 1.

S7720

SBE 13 HCl

SBE 13 HCl is a potent and selective PLK1 inhibitor with IC50 of 200 pM, >4000-fold selectivity over Aurora A kinase, Plk2 and Plk3.

Catalog No. Information Product Use Citations Product Validations
S1109

BI 2536

BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.

S2235

Volasertib (BI 6727)

Volasertib (BI 6727) is a highly potent Plk1 inhibitor with IC50 of 0.87 nM in a cell-free assay. It shows 6- and 65-fold greater selectivity against Plk2 and Plk3. Phase 3.

S1362

Rigosertib (ON-01910)

Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Phase 3.

S2193

GSK461364

GSK461364 inhibits purified Plk1 with Ki of 2.2 nM in a cell-free assay. It is more than 1000-fold selective against Plk2/3. Phase 1.

S1485

HMN-214

HMN-214 is a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.

S7552New

CFI-400945

CFI-400945 is an orally active, potent and selective polo-like kinase 4(PLK4) inhibitor with Ki value of 0.26 nM.

S2898

MLN0905

MLN0905 is a potent inhibitor of PLK1 with IC50 of 2 nM.

S7248

Ro3280

RO3280 is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.

S7255

NMS-P937 (NMS1286937)

NMS-P937 (NMS1286937) is an orally available, selective Polo-like Kinase 1 (PLK1) inhibitor with IC50 of 2 nM, 5000-fold selectivity over PLK2/PLK3. Phase 1.

S7720

SBE 13 HCl

SBE 13 HCl is a potent and selective PLK1 inhibitor with IC50 of 200 pM, >4000-fold selectivity over Aurora A kinase, Plk2 and Plk3.

Tags: PLK inhibition | PLK activation | PLK1 cancer | PLK1 phosphorylation | PLK1 pathway | PLK1 activation | PLK1 signaling | PLK1 kinase assay | PLK pathway | PLK inhibitors cancer | PLK1 inhibitor development | PLK inhibitor review